常青科技(603125.SH):擬100億元投建高分子新材料生產基地,規劃建設年產能偏苯三酸酐8萬噸等
格隆匯5月15日丨常青科技(603125.SH)公佈,公司擬通過全資子公司江蘇常青樹新材料科技(泰州)有限公司在泰州市高港區投資建設高分子新材料生產基地,為公司未來持續發展奠定堅實的基礎。泰州生產基地項目規劃遠期投資總額約100億元,分三期實施。其中一期項目(本項目)初步規劃投資金額約30億元(最終以實際投資金額為準),二期、三期項目尚無明確的投資規劃,如有後續進展將另行履行審議和信息披露程序。
項目名稱:高分子新材料生產基地(一期),本項目規劃建設年產能偏苯三酸酐8萬噸、均苯三甲酸1萬噸、二異丙苯系列產品共計11萬噸、(間/對)苯二酚8萬噸、間甲酚2萬噸、芳香基二元叔碳醇2萬噸、3,4二甲基苯甲醛0.5萬噸、甲基異丁基甲醇2萬噸以及聯產品等共計約8萬噸。(上述產品及產能為本項目初步規劃,未來可能根據實際實施情況調整)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.